InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Share Price

Current share price for CU6 : $2.140 0.04 (1.90%)+

Clarity Pharmaceuticals Ltd (CU6), an ASX-listed company, operates as a clinical stage radiopharmaceutical entity focused on treatment of serious diseases. The organisation develops TCTs based on the SAR Technology Platform for treatment of cancers.

CU6 General Information +

ASX Code CU6
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 798
CU6 Share Price $2.140
Day High $2.320
Day Low $2.080
Last Close $2.100
CU6 Share Price Movement $0.04 ( 1.90% )
Prices as at 16:40, 30 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Clarity Pharmaceuticals Ltd (CU6) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Clarity Pharmaceuticals Ltd (CU6) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clarity Pharmaceuticals Ltd (CU6) price-sensitive announcements

CU6 - Data on SAR-bisPSMA to be presented at EANM
Clarity Pharmaceuticals Ltd presented data on their product 67Cu-SAR-bisPSMA at the EANM 2
Clarity Pharmaceuticals Ltd (CU6)
29 Jun 2026 | 9:56 AM
CU6 - Clarity receives $9.8 million R&D tax incentive refund
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, announced recei
Clarity Pharmaceuticals Ltd (CU6)
14 May 2026 | 9:43 AM
CU6 - Quarterly Activities/Appendix 4C Cash Flow Report
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, released its Qu
Clarity Pharmaceuticals Ltd (CU6)
30 Apr 2026 | 12:24 PM
CU6 - Clarity signs a Commercial Manufacturing Agreement
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, announced the s
Clarity Pharmaceuticals Ltd (CU6)
14 Apr 2026 | 8:33 AM

Clarity Pharmaceuticals Ltd (CU6) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Data on SAR-bisPSMA to be presented at EANM 29 Jun 2026 9:56AM $1.815 $2.140 risen by 17.91%
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Clarity celebrates 100-employee milestone 26 Jun 2026 9:36AM $2.040 $2.140 risen by 4.90%
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Ceasing to be a substantial holder 25 Jun 2026 5:17PM $2.040 $2.140 risen by 4.90%
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Ceasing to be a substantial holder 22 Jun 2026 5:12PM $2.030 $2.140 risen by 5.42%
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Change in substantial holding 18 Jun 2026 5:21PM $2.190 $2.140 fallen by 2.28%
Clarity Pharmaceuticals Ltd (CU6)
ORDINARY FULLY PAID
Health Care $798 Becoming a substantial holder 17 Jun 2026 5:56PM $2.210 $2.140 fallen by 3.17%

CU6 Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$34.40 21.60% 0.00 0.00 0.00% 0.0%
2026F C2 -$28.30 40.50% 0.00 0.00 0.00% 0.0%
2025A -$64.30 -$20.10 30.00% 0.00 0.00 0.00% 0.0%

CU6 Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Clarity Pharmaceuticals Ltd (CU6) $677M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,547M -0.7857 0.0743 1.2000 52.4280 48.8000 22.1818 0.00% 0.00% 0.00%

CU6 Directors

Name Position Start Date
Dr Alan John Taylor Executive Chairman, Executive Director 28 Nov 2013
Ms Michelle Parker Executive Director 20 Sep 2024
Ms Rosanne Elizabeth Robinson Lead Independent Director, Non-Executive Director 19 Oct 2010
Dr Christopher Graham Roberts Non-Executive Director 24 Mar 2016

Clarity Pharmaceuticals Ltd (CU6) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
20 Apr 2026 PARKER, Michelle Sell Direct Shares 360,896 $3.056 $1,102,717.728
25 Nov 2025 PARKER, Michelle Issued Options 511,810 $1.616 $827,269.000
25 Nov 2025 BIGGIN, Colin Issued Options 487,439 $1.616 $787,875.000

See all changes in directors' interest & trades for Clarity Pharmaceuticals Ltd (CU6) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CU6 Management

Name Position
Mr David Green Chief Financial Officer
Robert Cochrane Vickery Chief Financial Officer,Company Secretary

CU6 Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clarity Pharmaceuticals Ltd (CU6). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
24,366,695 (6.55%) HSBC Custody Nominees Pty Ltd
22,096,014 (5.94%) Citicorp Nominees Pty Limited
20,704,111 (5.57%) J P Morgan Nominees Australia Pty Limited

CU6 Calendar of Events

Date Event
26 February 2027 Report (Interim)
04 September 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.